PCS12852 / Processa Pharma, Yuhan Corp - LARVOL DELTA

PCS12852, A NOVEL 5-HT4 AGONIST, IMPROVES GCSI SYMPTOM SCORES AND GASTRIC EMPTYING IN GASTROPARESIS PATIENTS (DDW 2023) - "PCS12852 0.5 mg, a potent and selective 5-HT 4 agonist given once daily for 28 days, improved gastric emptying in patients with gastroparesis as compared to placebo. A clinically meaningful reduction in the total ANMS GSCI-DD score and improvements in individual symptom scores were observed in the PCS12852 0.5 mg group. No significant adverse events were noted."

Clinical • Gastroenterology • Gastrointestinal Disorder • Pain

2435 AGA Gastroparesis and Small Intestinal Dysmotility (DDW 2023) - "Learning Objectives: Discover disturbances in the gastric muscular propria in idiopathic gastroparesis , Recognize the contribution of insulin-like growth factor to aging of gastric pacemaker cells, Understand the effects of cannabidiol, G-POEM, and PCS12852 in gastroparesis"

Gastrointestinal Disorder

"$PCSA PCS12852 Improves Gastric Emptying in Gastroparesis Patients https://t.co/IkGNGKPXWm" (@stock_titan)

Clinical • Gastrointestinal Disorder

MOMENTUM: Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis (clinicaltrials.gov) - P2a | N=25 | Completed | Sponsor: Processa Pharmaceuticals | Recruiting ➔ Completed

Trial completion • Gastrointestinal Disorder

MOMENTUM: Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis (clinicaltrials.gov) - P2a | N=24 | Recruiting | Sponsor: Processa Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder